Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985847 | 1.00 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL30728128 | 1.00 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL30728110 | 1.00 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL26985873 | 1.00 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL30728100 | 1.00 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL26986243 | 0.93 | SLC10A2 (0.38) | SLC10A2 | |
| SCHEMBL30728368 | 0.93 | SLC10A2 (0.38) | SLC10A2 | |
| SCHEMBL27128365 | 0.92 | ALDH1A1 (0.37) | SLC10A2 | |
| SCHEMBL30728079 | 0.91 | SLC10A2 (0.42) | SLC10A2 | |
| SCHEMBL26985899 | 0.91 | SLC10A2 (0.42) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | claimed |
| WO-2024008766-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-01-11 | — | — | WO | claimed |
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024121434-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| WO-2024008766-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024008766-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.